- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02562157
Endoscopic Gastroenteric Anastomosis With New Tissue Apposing Stent in the Management of Antro-pyloroduodenal Obstruction : Evaluation of Feasibility, Efficacy and Tolerance.
Gastroenteric Anastomosis With Natural Orifice Translumenal Endoscopic Surgery (NOTES) Using the New Fashionned Tissue Apposing Stent Axios® for the Treatment of Antro-pyloric or Duodenal Obstructions : Prospective Evaluation of Feasibility, Efficacy and Tolerance.
Achieving gastro-jejunal or duodenal anastomosis (GJA ) by exclusive endoscopically is a real goal for many years in the development and research of the transluminal endoscopic surgery (N.O.T.E.S). Endoscopic treatment, including palliative antro duodenal stenosis by metallic stent, although minimally invasive, causes problems in long-term secondary obstruction and migration. Surgical treatment of these strictures is associated with significant morbidity and mortality . The complication rate and severity of post-operative surgery after gastric bypass Roux-en-Y anastomosis or gastroduodenal fistulas remain close to 5% with a mortality of 1%. After 3 years of experimental research on porcine model, our team has developed a procedure of gastro duodenal anastomosis using transgastric endoscopic minimally invasive surgical technique (or NOTES) - LBA UMRT24 CERC laboratory , Aix-Marseille University , Faculty of Medicine North, with the aim to offer a credible alternative to conventional surgery.
Thus the investigators propose to conduct a pilot prospective intervenionnal study. The investigators hypothetized that this technique would reduce morbidity and mortality clinical but also economic consequences of surgery while making it possible to obtain excellent results permeability and long-term functionality. This method uses a new concept of tissue apposition with a fully covered metallic stent to create the anastomosis under endoscopy exclusively. Ten patients with antro duodenal obstructions requiring surgical or endoscopic bypass will be included as part of an interventional biomedical research that will be conducted in one expert center. The duration of the inclusions will be 18 months. Then, the stent will be removed three months after insertion, at the end of the healing process, and each patient will be followed for one year. The primary endpoint will be the assessment of the feasibility of the procedure for gastro duodenal anastomosis using tissue apposition stenting and NOTES in human being. The secondary endpoints will be the clinical efficacy, the long term (1 year) patency of the anastomosis, the procedure duration, adverse events, morbidity and mortality, the quality of life and the length of stay.
In case of failure of the NOTES procedure, the patient will be treated either by surgery or by conventional endoscopy according to the usual techniques without loss of chance. The risk / benefit ratio appears positive and a safety report will be issued after the first 4 inclusions. There will be no supplementary examination in patient follow-up in this study for which a CT iconography and biology are enough. The material used in the context of this work is consistent with the legislation on medical devices and has received CE Mark (tissue apposition fully covered stent Axios ®).
Study Overview
Status
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Jean Michel GONZALEZ, MD
- Email: Jean-michel.GONZALEZ@ap-hm.fr
Study Locations
-
-
-
Marseille, France, 13005
- Assistance Publique Hopitaux de Marseille
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Age > 18 years old
- Benign or malignant antropyloric or duodenal obstruction leaving free the 3rd and the 4th duodenum, confirmed by CT scan or endoscopy
- Patient having been hospitalized at least once for this indication, with failure of medical treatment and/or failure or impossibility of endoscopic treatment using metallic duodenal stenting.
- Patients having under nutrition with a weight loss > 10%
- Theorical indication of surgical gastroenteric anastomosis with operating contraindication or refusal of the surgery by the patient
- Indication validated during multidisciplinary meeting
- GOOSS score = 0 or 1
- Patient having received clear and complete information and given written consent
- Patient having medical care insurrance
Exclusion Criteria:
- Contraindication to general anesthesia
- Severe hemostasis and coagulation troubles : Prothrombin level < 50% and/or platelets level < 50G/l
- History of duodenal or gastric surgery
- Pregnancy or population of vulnerable patients
- Mental deficiency
- Voluntary withdrawal of informed consent
- Discontinuation by decision of the investigator or the promotor
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Patients with antro duodenal obstructions
NOTES gastroenteric anastomosis
|
Intradermal delivery of fractional CO2 laser-assisted hyaluronic acid in facial skin contouring
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Feasibility of the gastroenteric anastomosis
Time Frame: End of procedure (up to 2 hours)
|
Technical feasibility of the anstomosis endoscopically confirmed by the ability to perform the proceudre exclusively by endoscopy, and by opacification under contrast showing the patency and the absence of fistula.
|
End of procedure (up to 2 hours)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Clinical efficacy
Time Frame: 5 days to 6 months
|
GOOSS score increasing by 2 points after 4 weeks of follow-up ; Weight gain > 10%
|
5 days to 6 months
|
Long term patency
Time Frame: 15 days after stent removal, after 6 and 12 months
|
Ability to pass an inflated 15mm balloon and a large channel gastroscope
|
15 days after stent removal, after 6 and 12 months
|
Procedure duration
Time Frame: end of study (30 months)
|
end of study (30 months)
|
|
Morbidity evaluation
Time Frame: few days, 30 days, and late adverse events
|
Cotton classification
|
few days, 30 days, and late adverse events
|
Evaluation of quality of life
Time Frame: until 12 months
|
SF 36 Scale
|
until 12 months
|
Length of stay in hospitalization
Time Frame: end of last hospitalization (approximatively 18 months)
|
end of last hospitalization (approximatively 18 months)
|
|
Procedure learning curve
Time Frame: end of study (30 months)
|
end of study (30 months)
|
|
Mortality evaluation
Time Frame: up to 30 months
|
up to 30 months
|
Collaborators and Investigators
Investigators
- Study Director: Urielle DESALBRES, Director, Assistance Publique Hopitaux de Marseille
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimated)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- 2014-32
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Antro-pyloric and/or Duodenal Benign or Malignant Obstructions
-
University Hospital, ToulouseCompletedNeoplasm, Uncertain Whether Benign or MalignantFrance
-
Ethicon Endo-SurgeryCompletedBenign or Malignant Disease Indicated for ColectomyUnited States, Belgium, United Kingdom
-
University Hospital, BordeauxRecruitingMalignant or Benign PathologyFrance
-
University Hospital, BordeauxCompleted
-
Kantonsspital LiestalCompletedBenign or Early Malignant Lesion of the Distal Esophagus or Gastro-esophageal Junction Requiring Surgical ResectionSwitzerland
-
Integra LifeSciences CorporationCompletedBenign, Malignant Tumors or Other Soft Tissue Removal | Nephrectomy or Partial Nephrectomy With Parenchyma RemovalGermany, Italy
-
Methodist Health SystemRecruitingBenign or Malignant Pancreatic DiseasesUnited States
-
Yonsei UniversityRecruitingBenign or Malignant Diseases With Indication for Laparoscopic or Robotic Colorectal ResectionKorea, Republic of
-
Bordeaux Colorectal Institute AcademyRecruitingColorectal Surgery | Benign or Malignant Rectal or Colon TumorsFrance, Switzerland, Argentina, Belgium, Germany, Italy, Netherlands, Spain, United Kingdom
-
Duke UniversityTerminatedENDOBRONCHIAL ULTRASOUND - TRANSBRONCHIAL NEEDLE ASPIRATION | Benign and Malignant Mediastinal and Hilar Lymph Nodes Known or Suspected MalignancyUnited States
Clinical Trials on HYALURONIQUE ACIDE
-
Assistance Publique - Hôpitaux de ParisLaboratoires Vivacy; INTERmedic; Laboratoires IPRAD PHARMARecruiting
-
Centre Hospitalier Universitaire de NiceTerminatedDiabetic CardiomyopathiesFrance
-
Institut Cancerologie de l'OuestCompleted
-
Chinese Septic Shock NetworkCompleted
-
Assistance Publique - Hôpitaux de ParisTerminatedOsteoid OsteomaFrance
-
Neutec Ar-Ge San ve Tic A.ŞUnknownAcute Exacerbation of Chronic Bronchitis | Community-Acquired PneumoniaeTurkey
-
Centre Hospitalier de MontaubanCompletedPostoperative HemorrhageFrance
-
Massachusetts General HospitalNational Institutes of Health (NIH)Withdrawn
-
Mclean HospitalStanley Medical Research InstituteCompletedBipolar DepressionUnited States
-
Institut de Médecine et d'Epidémiologie Appliquée...Completed